Category · SERMs
SERMs: selective estrogen modulators.
Drugs that block estrogen at some receptors while mimicking it at others — the kind of selective action that makes them useful across very different indications. Approved drugs with strong evidence in their primary uses, widely repurposed off-label for hormonal restart, fertility, and testosterone management.
Tamoxifen and raloxifene are best known for breast cancer and osteoporosis — both have decades of large RCTs behind them. Clomiphene is the long-standing ovulation-induction drug and is widely used off-label for male hypogonadism. Enclomiphene is its isolated trans-isomer, marketed more recently as a testosterone-raising agent that preserves fertility. All four hit the estrogen receptor with different tissue specificity, which is why their side-effect profiles differ.
Important: the FDA-approved indication for each SERM is well-evidenced (grade 10 territory). Off-label uses common in the enhanced community — post-cycle restart, maintaining natural testosterone — are real but more sparsely studied, and we grade on what the data actually shows, not what's customary.
- 10/10 · Established Clomiphene Medically: ovulation induction in women. Off-label/PED-support: raising endogenous testosterone in hypogonadal men and restarting the HPG axis after steroid use.
- 10/10 · Established Raloxifene Medically: prevention and treatment of postmenopausal osteoporosis, and reduction of invasive breast-cancer risk in two postmenopausal populations. Off-label/illicit: estrogen-receptor blockade in breast tissue by male anabolic-steroid users (gynecomastia management, post-cycle attempts).
- 10/10 · Established Tamoxifen Medically: ER-positive breast cancer (treatment, adjuvant, and risk reduction) and DCIS; off-label gynecomastia. In the PED context: blunting estrogen-driven side effects from anabolic steroids and attempting post-cycle testosterone restart.
- 8/10 · Good Enclomiphene Medically (off-label/investigational): raising endogenous testosterone in men with secondary hypogonadism while preserving fertility. In the PED context: restarting endogenous testosterone after steroid use and countering estrogenic side effects.
Reading this class honestly
SERMs are the most heavily-evidenced class in the enhanced-community toolbox — but the evidence covers their approved uses, not all the off-label patterns. See the individual profiles for the split. For the post-cycle / restart context see also peptides & anti-doping.